The most recent Vertex Pharmaceuticals (VRTX) insider transaction: Grunsven Jasper Van (Evp, Cp And Nppo) received 8,682 shares as a grant or award on Sep 8, 2026, reported on Form 4 on Sep 10, 2026. So far in the quarter ending Dec 31, 2026, insider holdings showed no net buying or selling.
In the last 12 months, insiders at Vertex Pharmaceuticals made open-market sales of $158.1 million (342.36K shares) and bought no shares on the open market.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Reshma Kewalramani | Ceo President | 98,278 | 0 | 98,278 | 16.1% | 03 Mar, 2026 |
| 2 | Amit Sachdev | Evp Chief Patient Ext Af Off | 66,512 | 0 | 66,512 | 10.9% | 23 Jul, 2026 |
| 3 | Stuart A Arbuckle | Evp, Coo | 63,368 | 0 | 63,368 | 10.4% | 02 Jul, 2025 |
| 4 | Ourania Tatsis | Evp, Chief Reg. Quality Off. | 53,572 | 0 | 53,572 | 8.8% | 23 Jul, 2026 |
| 5 | Charles F Jr Wagner | Evp, Co Fo | 47,042 | 0 | 47,042 | 7.7% | 26 Feb, 2026 |
| 6 | Bruce I Sachs | Director | 39,000 | 0 | 39,000 | 6.4% | 31 Aug, 2026 |
| 7 | Jeffrey M Leiden | Executive Chairman | 34,797 | 0 | 34,797 | 5.7% | 26 Feb, 2026 |
| 8 | David Altshuler | Evp, Chief Scientific Officer | 34,477 | 0 | 34,477 | 5.7% | 26 Jan, 2026 |
| 9 | Bastiano Sanna | Evp, Cell Genetic Therapies | 32,038 | 0 | 32,038 | 5.3% | 09 May, 2023 |
| 10 | Joy Liu | Evp And Chief Legal Officer | 19,131 | 0 | 19,131 | 3.1% | 06 Jul, 2026 |
| 11 | Edward Morrow Iii Atkinson | Evp, Chief Technical Ops. Off. | 18,432 | 0 | 18,432 | 3.0% | 26 Feb, 2026 |
| 12 | Carmen Bozic | Evp And Cmo | 15,337 | 0 | 15,337 | 2.5% | 30 Jun, 2026 |
| 13 | Jonathan Biller | Evp And Chief Legal Officer | 13,659 | 0 | 13,659 | 2.2% | 26 Feb, 2026 |
| 14 | Kristen Ambrose | Svp Chief Accounting Officer | 11,624 | 0 | 11,624 | 1.9% | 01 Sep, 2026 |
| 15 | Duncan Mckechnie | Evp, Chief Commercial Officer | 11,001 | 0 | 11,001 | 1.8% | 07 Jul, 2026 |
| 16 | Grunsven Jasper Van | Evp, Cp And Nppo | 8,682 | 0 | 8,682 | 1.4% | 10 Sep, 2026 |
| 17 | Alan M Garber | Director | 7,344 | 0 | 7,344 | 1.2% | 05 May, 2026 |
| 18 | Mark E. Bunnage | Evp, Chief Scientific Officer | 7,284 | 0 | 7,284 | 1.2% | 19 May, 2026 |
| 19 | Terrence C Kearney | Director | 6,536 | 0 | 6,536 | 1.1% | 14 Aug, 2023 |
| 20 | Lloyd Carney | Director | 6,315 | 0 | 6,315 | 1.0% | 20 Nov, 2025 |
| 21 | Sangeeta N. Bhatia | Director | 4,924 | 0 | 4,924 | 0.8% | 05 May, 2026 |
| 22 | Diana Mckenzie | Director | 2,378 | 0 | 2,378 | 0.4% | 05 May, 2026 |
| 23 | Nancy Thornberry | Director | 2,109 | 0 | 2,109 | 0.3% | 05 May, 2026 |
| 24 | Yuchun Lee | Director | 1,875 | 0 | 1,875 | 0.3% | 31 Jan, 2023 |
| 25 | Suketu Upadhyay | Director | 1,558 | 0 | 1,558 | 0.3% | 05 May, 2026 |
| 26 | Jennifer Schneider | Director | 1,394 | 0 | 1,394 | 0.2% | 05 May, 2026 |
| 27 | Michel Lagarde | Director | 1,132 | 0 | 1,132 | 0.2% | 10 Oct, 2023 |
| 28 | Margaret G Mcglynn | Director | 178 | 0 | 178 | 0.0% | 03 May, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 08 Sep, 2026 | Grunsven Jasper Van | Evp, Cp And Nppo | Acquired A | 8,682 | $0.00 | $0 | 8,682 | Direct |
| 28 Aug, 2026 | Kristen Ambrose | Svp Chief Accounting Officer | Acquired A | 5,000 | $0.00 | $0 | 11,624 | Direct |
| 27 Aug, 2026 | Bruce I Sachs | Director | Disposed G | 6,000 | $0.00 | $0 | 39,000 | Direct |
| 21 Jul, 2026 | Amit Sachdev | Evp Chief Patient Ext Af Off | Acquired A | 8,251 | $0.00 | $0 | 66,512 | Direct |
| 21 Jul, 2026 | Ourania Tatsis | Evp, Chief Reg. Quality Off. | Acquired A | 8,251 | $0.00 | $0 | 53,572 | Direct |
| 15 Jul, 2026 | Bruce I Sachs | Director | Acquired A | 100 | $475.28 | $47.50K | 15,772 | Direct |
| 15 Jul, 2026 | Alan M Garber | Director | Acquired A | 32 | $475.28 | $15.00K | 65 | Direct |
| 02 Jul, 2026 | Ourania Tatsis | Evp, Chief Reg. Quality Off. | Disposed S | 1,500 | $524.99 | $787.49K | 45,321 | Direct |
| 02 Jul, 2026 | Duncan Mckechnie | Evp, Chief Commercial Officer | Disposed S | 1,541 | $519.00 | $799.78K | 11,001 | Direct |
| 01 Jul, 2026 | Joy Liu | Evp And Chief Legal Officer | Disposed S | 828 | $502.71 | $416.24K | 19,131 | Direct |
| 26 Jun, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 596 | $482.50 | $287.57K | 15,337 | Direct |
| 18 Jun, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 1,020 | $462.17 | $471.41K | 15,933 | Direct |
| 15 Jun, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 4,062 | $450.00 | $1.83Mn | 16,953 | Direct |
| 05 Jun, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 1,745 | $450.00 | $785.25K | 21,015 | Direct |
| 01 Jun, 2026 | Joy Liu | Evp And Chief Legal Officer | Disposed S | 828 | $439.91 | $364.25K | 19,959 | Direct |
| 29 May, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 1,974 | $450.00 | $888.30K | 22,760 | Direct |
| 15 May, 2026 | Mark E. Bunnage | Evp, Chief Scientific Officer | Disposed S | 33 | $453.45 | $14.96K | 7,284 | Direct |
| 15 May, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 1,354 | $453.45 | $613.97K | 24,734 | Direct |
| 12 May, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 6,988 | $450.00 | $3.14Mn | 26,088 | Direct |
| 01 May, 2026 | Michel Lagarde | Director | Acquired A | 2,866 | $0.00 | $0 | 2,866 | Direct |